Correction: Candidate variants in DNA replication and repair genes in early-onset renal cell carcinoma patients referred for germline testing

Elena V. Demidova, Ilya G. Serebriiskii, Ramilia Vlasenkova, Simon Kelow, Mark Andrake, Tiffiney R. Hartman, Tatiana Kent, James Virtucio, Gail Rosen, Richard T. Pomerantz, Roland L. Dunbrack, Erica A. Golemis, Michael J. Hall, David Y.t. Chen, Mary B. Daly, Sanjeevani AroraBMC 2023 · DOI · OpenAlex

Abstract

Early-onset renal cell carcinoma (eoRCC) often lacks mutations in classic susceptibility genes like VHL or MET. This study investigates the role of germline variants in DNA replication and repair (DRR) genes as potential drivers of eoRCC. Through whole exome sequencing (WES) and pedigree analysis of 22 patients, researchers identified significant variants in DNA polymerases and other DRR pathways. These variants are associated with high tumor mutational burdens (TMB) and multi-cancer family histories, suggesting that non-canonical DRR pathways play a significant role in kidney cancer predisposition.

Introduction

Renal cell carcinoma (RCC) typically presents in older populations. When diagnosed in younger patients, a hereditary component is often suspected. However, a significant portion of early-onset cases test negative for known kidney cancer genes. This research explores the hypothesis that rare variants in the broader DRR machinery—the systems responsible for ensuring accurate DNA copying and repair—contribute to eoRCC predisposition.

Methods

The study utilized a multi-faceted approach combining clinical genetics and high-throughput sequencing. Whole Exome Sequencing (WES) was performed on a primary cohort of 22 patients referred for germline testing due to early-onset renal cell carcinoma. Candidate variants were filtered based on predicted pathogenicity and their involvement in DNA replication and repair (DRR) pathways. Detailed family histories were mapped through pedigree analysis to correlate specific genetic variants with multi-generational cancer patterns. To assess the molecular impact, Sanger sequencing was employed to validate variants and evaluate for Loss of Heterozygosity (LOH) in tumor tissue. Finally, comparative genomics were conducted by benchmarking the cohort's mutational profiles against 897 RCC samples from The Cancer Genome Atlas (TCGA), categorized by histological subtype.

Key Findings

The Polymerase Connection and High TMB

Variants in DNA polymerases such as POLE, POLD1, and POLH emerged as significant. These enzymes are critical for DNA "proofreading" during replication. Mutations in these genes can lead to a "mutator phenotype," resulting in significantly elevated TMB. Specifically, patients with POLD1 (V759I) and POLE (W1624X) variants showed TMBs of 12.85 and 14.44 mutations/MB, respectively—far exceeding typical RCC levels. Notably, these tumors remained microsatellite stable (MSS), distinguishing them from Mismatch Repair (MMR)-deficient cancers.

Molecular characterization of eoRCC variants including TMB and Sanger sequencing results.

Pedigree and Pathway Enrichment

Pedigree analysis revealed striking multi-cancer histories in families carrying these variants. For instance, a proband with POLD1 and POLH variants belonged to a family with incidences of breast, bone, skin, stomach, and pancreatic cancers. Beyond polymerases, variants clustered in pathways like Homologous Recombination (HR) and Fanconi Anemia (FA), highlighting these as critical areas for future eoRCC research.

Family pedigrees and distribution of candidate variants across DNA repair pathways.

Non-Canonical Tumorigenesis

Sanger sequencing indicated that tumors often retained the wild-type (normal) allele of the mutated DRR gene. This suggests that these variants may not follow the traditional "two-hit" tumor suppressor model. Instead, they might exert a dominant-negative effect or create a genomic environment that facilitates the accumulation of other oncogenic mutations, driving cancer progression even in the presence of a healthy allele.

Conclusion and Future Directions

This pilot study highlights the importance of looking beyond classic susceptibility genes in eoRCC. The identification of DRR variants, particularly in DNA polymerases, provides a new lens for understanding kidney cancer predisposition. While the cohort size is small, these findings suggest that patients with high-TMB tumors may benefit from different clinical management, including potential eligibility for immune checkpoint inhibitor therapies. Future work will focus on functional validation of these variants and expanding the cohort to establish statistical prevalence.

Summary updated

Abstract

Supplementary table 1. List of candidate genes for WES analysis.Supplementary table 2
BibTeX
@inproceedings{demidova2023correction,
  author = {Elena V. Demidova and Ilya G. Serebriiskii and Ramilia Vlasenkova and Simon Kelow and Mark Andrake and Tiffiney R. Hartman and Tatiana Kent and James Virtucio and Gail Rosen and Richard T. Pomerantz and Roland L. Dunbrack and Erica A. Golemis and Michael J. Hall and David Y.T. Chen and Mary B. Daly and Sanjeevani Arora},
  title = {{Correction: Candidate variants in DNA replication and repair genes in early-onset renal cell carcinoma patients referred for germline testing}},
  booktitle = {BMC},
  year = {2023},
  doi = {10.1186/s12864-023-09486-z},
}
Figure